摘要
目的测定2型糖尿病(T2DM)患者血浆成纤维细胞生长因子21(FGF-21)的浓度,观察罗格列酮对FGF-21的影响。方法 34例单用二甲双胍降糖治疗无效的T2DM患者加用罗格列酮(RGZ组)治疗12周,治疗前后测定FGF-21及相关代谢指标。同时测定初发2型糖尿病(T2DM组)30例,正常对照组(NC组)30例。结果 RGZ组和T2DM组FGF-21水平均高于NC组(P均<0.05),但两组间差异无统计学意义。联合治疗后,RGZ组血浆FGF-21水平显著降低(1.59±0.11 vs.1.87±0.11,P<0.05)。结论 FGF-21可能在罗格列酮调节代谢的机制中具有重要作用。
Objective To investigate the effects of rosiglitazone on plasma fibroblast growth factor- 21 （FGF-21） levels in patients with type 2 diabetes mellhus. Methods 30 patients with newly- diagnosed T2DM （T2DM）, 34 type 2 diabetic patients with poor glycemic control undergoing rosiglitazone therapy （RGZ） and 30 sex-and age-matched normal controls （NC） were enrolled in the study. RGZ group was treated with rosiglitazone in addition to the previous medications for 12 weeks. Plasma FGF-21 levels were measured with a radioimmunoassay. The relationship between plasma FGF21 and anthropometric and metabolic parameters was also analyzed. Results Fasting plasma FGF-21 levels were higher in T2DM and RGZ than in NC （1.81±0.11 vs. 1.87＋0.11vs. 1.52±0.10μg/L, P〈0. 05）, but there was no difference between T2DM and RGZ. Fasting plasma FGF-21 levels were decreased significantly in RGZ group after treatment with rosiglitazone （1.59±0.11 vs. 1.87±0.11 μg/L, P〈0.05）. In RGZ group, multiple regression analysis showed that HbA1c （β= -0.242, P=0.026）, Fins（β= -0.101,P= 0. 0015） and HOMA-IR（β= 1. 273, P= 0. 003） were independently influencing factors for plasma FGF-21 levels. Conclusions In T2DM group,plasma FGF-21 level is increased,and treatment of these patients with the rosiglitazone significantly reduces plasma FGF21 levels. These data suggest that FGF-21 may play a role in the rosiglitazone action.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2010年第10期774-777,共4页
Chinese Journal of Diabetes
基金
国家自然科学基金项目(30270631
30370671)
国家教委春晖计划资助项目(2003-56)
